Fundraising Fox

Cagent Vascular

Wayne, US · Founded 2014 · Delaware corporation · 105 employees on LinkedIn · 3 known investors

Cagent Vascular develops endovascular medical devices, including the Serranator PTA Serration Balloon Catheter, for the treatment of vascular disease. The company serves vascular surgeons and interventionalists in the medical device industry.

HardwareHealthtechMedical Devices

Founders & leadership

BWBrian Walsh
Brian WalshinChairman & Chief Executive Officer
PJPeter Johansson
Peter JohanssoninChief Quality & Compliance Officer, VP Engineering
PWPaul Wilson
Paul WilsoninChief Commercial Officer
MCMatt Condron
Matt CondroninSVP of Operations
CLCorey Latanision
Corey LatanisioninSVP of Marketing & International Sales
PS
Peter SchneiderChief Medical Advisor, Co-Founder
CA
Carol A. BurnsNamed on SEC filing
RGRobert Giasolli
Robert GiasolliinFounder, CTO, and VP of Research and Development
FL
Fred LampropoulosNamed on SEC filing
DM
Dennis McGrathNamed on SEC filing

Board

CTCasey Tansey
Casey TanseyBoard directorGeneral Partner at US Venture Partners
MM
Marc-Andre MarcotteBoard director

Investors · 3

US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
Astoria Health Investorsreported · 2 sourcesLas Vegas
U.S. Venture PartnersreportedMinneapolis

Funding

SEC filings, press & company announcements

$114M disclosed across 7 rounds · 2014–2026

▶$24.5MraisedJun 2026 · 51 investors · Other Health Care
Rule 506(b)
Cagent Vascular has raised $41 Million in new Series D Funding - intelligence360intelligence360.news · Jun 2026Cagent Vascular Raises $41 Million to Advance IVL Platform - MyChesComychesco.com · Jun 2026
Officers, directors & promoters on the filing
  • Bruce Brumfield, Jr.Director
  • Casey TanseyDirector
  • Aaron GreenExecutive Officer
  • Marc-Andre MarcotteDirector
  • Tak CheungDirector
  • Brian WalshExecutive Officer, Director
Offering amount
$41M
Amount sold
$24.5M
First sale
May 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$28.7MraisedFeb 2024 · 26 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian WalshDirector
  • Dennis McGrathExecutive Officer
  • Casey TanseyDirector
  • Marc-Andre MarcotteDirector
  • Bruce J BlumfieldDirector
  • Carol A. BurnsExecutive Officer, Director
Offering amount
$30.3M
Amount sold
$28.7M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.2MraisedMay 2023 · 41 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian WalshDirector
  • Greg FreddeDirector
  • Dennis McGrathExecutive Officer, Director
  • Mike MarkertDirector
  • Carol BurnsExecutive Officer, Director
  • Peter SchneiderDirector
  • Marc-Andre MarcotteDirector
Offering amount
$11M
Amount sold
$7.2M
First sale
Apr 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.5MraisedJun 2021 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Carol BurnsExecutive Officer, Director
  • Mike MarkertDirector
  • Peter SchneiderDirector
  • Brian WalshDirector
  • Dennis McGrathExecutive Officer, Director
  • Marc-Andre MarcotteDirector
  • Fred LampropoulosDirector
Offering amount
$9.5M
Amount sold
$9.5M
First sale
Jun 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedMay 2018 · 31 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter SchneiderDirector
  • Carol A. BurnsExecutive Officer, Director
  • Brian WalshDirector
  • Robert GiasolliDirector
  • Fred LampropoulosDirector
  • Dennis McGrathExecutive Officer, Director
Offering amount
$12M
Amount sold
$3M
First sale
Jul 2017
Incorporated
Limited Liability Company, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50KraisedJun 2014 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter SchneiderDirector
  • Robert GiasolliDirector
  • Dennis McGrathExecutive Officer, Director
  • Carol A. BurnsExecutive Officer, Director
Offering amount
$6M
Amount sold
$50K
First sale
Jun 2014
Incorporated
Limited Liability Company, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 6

by search overlap
Boston Scientific18 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Rf Surgical16 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Vantis Vascular12 shared keywordsVantis Vascular develops vascular intervention technology, including the CrossFast integrated vascular delivery system with an auto-locking inner monorail microcatheter and outer delivery catheter for complex PCI procedures. Founded by physicians, the company is also developing next-generation intravascular lithotripsy (IVL) and peripheral below-the-knee (BTK) solutions for vascular interventionalists.</parameter> <parameter name="founders">[{"full_name": "Jason Turner", "title": "Chief Executive Officer"}, {"full_name": "Tim Fischell", "title": "Chief Medical Officer"}, {"full_name": "Frank Saltiel", "title": "Chief Clinical Officer"}, {"full_name": "Gary McCord", "title": "Chief Commercial Officer"}, {"full_name": "Mike Mirizzi", "title": "Chief Technology Officer"}, {"full_name": "Marc Monahan", "title": "Chief Financial Officer"}]</parameter> <parameter name="hq_city">San Jose
AngioDynamics9 shared keywordsAngioDynamics develops and manufactures medical devices aimed at treating serious diseases and improving patient outcomes. Founded in 1988, the company serves healthcare professionals and operates globally across North America, Europe, the Middle East, and South America.
Access Vascular7 shared keywordsAccess Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications. The company designs and manufactures its medical devices for clinical use in the United States.
Innova Vascular7 shared keywordsInnova Vascular is a medical device company focused on the vascular space, led by a founder with a background in developing and commercializing vascular medical devices. The page provides limited detail about the company's specific products.

Companies competing with Cagent Vascular for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Cagent Vascular has raised $41 Million in new Series D Funding - intelligence360intelligence360.news · Jun 2026Cagent Vascular Raises $41 Million to Advance IVL Platform - MyChesComychesco.com · Jun 2026Cagent Vascular Closes $41 Million Series D Financing With Guidance From Troutman Pepper Locke - Troutman Pepper Locketroutman.com · May 2026Cagent secures $41m to launch coronary artery platformbioxconomy.com · May 2026Cagent Vascular Raises $41.0M Series | Signalbasetrysignalbase.com · May 2026Cagent Vascular reports first-in-human IVL cases, raises $41Mmassdevice.com · May 2026Cagent Vascular Reports First Human Use of Serranator® SONIC IVL System and Closes Oversubscribed $41M Series D Financingbusinesswire.com · May 2026 · press releaseCagent Vascular Raises $30 Million Series C Financingbusinesswire.com · Feb 2024

Frequently asked questions

What does Cagent Vascular do?
Cagent Vascular develops endovascular medical devices, including the Serranator PTA Serration Balloon Catheter, for the treatment of vascular disease. The company serves vascular surgeons and interventionalists in the medical device industry.
Who are Cagent Vascular's investors?
Cagent Vascular's investors include US Venture Partners, Astoria Health Investors, U.S. Venture Partners.
How much funding has Cagent Vascular raised?
Cagent Vascular has disclosed $114M raised across 7 rounds.
Where is Cagent Vascular headquartered?
Cagent Vascular is headquartered in Wayne, US.